PtBio

Founded in 2019 and based in Higashihiroshima, Japan, PtBio Inc. , d. b. a.

PtBio, operates as a company that provides genome editing tool development, genome analysis services, bioinformatics, data driven breeding support, and bio manufacturing support, offering integrated research, development, and implementation services to partners in healthcare, agriculture, food, energy, and biotechnology sectors. In March 2026, PtBio raised an undisclosed amount of venture funding from Chugin Capital Partners. PtBio Inc. specializes in advanced biotechnology solutions, primarily focusing on genome editing and BioDX services.

Their core offerings include the development of Platinum TALENs and ZF-ND1 genome editing tools, enabling precise modifications in various organisms for applications in agriculture, aquaculture, and medical therapies. Additionally, they are involved in data-driven breeding practices for perilla plants, gene therapies for rare eye diseases, and the development of hypoallergenic eggs for those with egg allergies. Their innovations target diverse markets, including Japan, Southeast Asia, and potentially beyond. PtBio Inc.

operates on a business-to-business (B2B) model, providing genomic services to sectors like agriculture, pharmaceuticals, and environmental management. The company engages in partnerships with research institutions, agricultural firms, and biotech companies to deliver tailored solutions. Revenue is generated through contracts for genome editing services, which may involve fixed project fees or milestone payments. The BioDX services may also operate on a subscription basis, providing clients with continuous access to data analytics.

As of March 2026, the company plans to scale bio DX services, commercialize allergy reduced eggs, expand partnerships, advance gene therapy programs, and grow operations.